Wednesday, July 8, 2026

Drug profile · INN

pentostatin

pentostatin (NIPENT) is a adenosine deaminase inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — pentostatin
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

pentostatin (NIPENT) is a adenosine deaminase inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN pentostatin
Brand NIPENT
Mechanism Adenosine deaminase inhibitor
Target Adenosine deaminase
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Adenosine deaminase inhibitor

Primary target: Adenosine deaminase

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is pentostatin?

pentostatin (NIPENT) is a adenosine deaminase inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for pentostatin?

NIPENT is a marketed brand name for pentostatin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of pentostatin?

pentostatin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.